All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Is Ozempic safe, effective, and right for you?

What Ozempic actually is, how it works, who it's FDA-approved for, safety data from 8+ years of trials, and when compounded semaglutide is appropriate.

By FormBlends Editorial Research|Reviewed by FormBlends Medical Team||
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

See your GLP-1 options in about 2 minutes. Free and private. See my options →
  • Ozempic is FDA-approved for type 2 diabetes, not weight loss, though it causes significant weight reduction as a side effect (14.9% body weight at 68 weeks in STEP 1)
  • The safety profile across 8+ years of clinical trials shows serious adverse events in 3.4% of patients, comparable to placebo at 3.2%, with nausea being the most common side effect
  • Compounded semaglutide contains the same active ingredient but is not FDA-approved and exists legally only during periods when brand-name supply cannot meet demand
  • The medication works by mimicking GLP-1, a hormone that slows digestion, reduces appetite, and improves insulin response, not by speeding up metabolism or burning fat directly

Ozempic is a brand-name injectable medication containing semaglutide, a GLP-1 receptor agonist FDA-approved for type 2 diabetes management. It lowers blood sugar, reduces cardiovascular risk, and causes weight loss averaging 14 to 17 pounds over 68 weeks. Safety data from trials involving over 9,000 patients shows serious adverse events occur at rates comparable to placebo.

  1. What Ozempic actually is (and what it isn't)
  2. The FDA approval history and what it means
  3. How semaglutide works: the mechanism explained
  4. The clinical trial safety data across 8+ years
  5. Efficacy: what the published outcomes show
  6. What most articles get wrong about Ozempic vs Wegovy
  7. The compounded semaglutide question: when it's legal and appropriate
  8. Who should not take Ozempic or any semaglutide product
  9. The decision framework: is this medication right for your situation?
  10. Side effects ranked by frequency and severity
  11. The cost question: brand vs compounded economics
  12. FAQ
  13. Sources

What Ozempic is and how it differs from Wegovy

Ozempic is the brand name for injectable semaglutide manufactured by Novo Nordisk. The medication comes in pre-filled pens delivering 0.25 mg, 0.5 mg, 1 mg, or 2 mg doses once weekly via subcutaneous injection.

The active ingredient, semaglutide, is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a hormone your intestines naturally produce after eating. The synthetic version has a half-life of 7 days compared to GLP-1's natural half-life of 2 minutes, which is why it works as a once-weekly injection rather than requiring continuous infusion.

What Ozempic is:

  • An FDA-approved medication for type 2 diabetes
  • A GLP-1 receptor agonist that improves glycemic control
  • A medication that reduces major adverse cardiovascular events (MACE) by 26% in diabetic patients with established cardiovascular disease (SUSTAIN-6 trial)
  • A prescription-only medication requiring provider supervision

What Ozempic is not:

  • FDA-approved for weight loss (that's Wegovy, a different dosing formulation of the same molecule)
  • A metabolism booster or fat burner
  • A substitute for diet and exercise
  • Appropriate for type 1 diabetes
  • A cosmetic weight-loss drug for people at healthy body weight

The confusion between Ozempic and Wegovy is the single biggest source of misinformation in this category. Both contain semaglutide. Ozempic is approved for diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at doses up to 2.4 mg weekly. The molecule is identical. The indication, dosing schedule, and insurance coverage differ.

The FDA approval history and what it means

The FDA approval timeline for semaglutide reveals how the medication's use evolved based on accumulating evidence:

DateApprovalIndicationMaximum dose
December 2017Ozempic (injectable semaglutide)Type 2 diabetes1 mg weekly
September 2019Rybelsus (oral semaglutide)Type 2 diabetes14 mg daily
June 2021Wegovy (injectable semaglutide)Chronic weight management2.4 mg weekly
October 2022Ozempic dose expansionType 2 diabetes2 mg weekly

The approval pathway matters because it defines what claims manufacturers can legally make and what insurance will cover. Ozempic's FDA approval is based on the SUSTAIN clinical trial program (SUSTAIN 1 through 10), which enrolled over 9,000 patients with type 2 diabetes and measured glycemic control as the primary endpoint.

Weight loss was a secondary endpoint in those trials. Patients lost weight consistently, which led Novo Nordisk to conduct separate trials (STEP 1 through 5) in non-diabetic patients with obesity. Those trials became the basis for Wegovy's approval.

The practical consequence: if you have type 2 diabetes and obesity, insurance typically covers Ozempic. If you have obesity without diabetes, insurance typically does not cover Ozempic but may cover Wegovy. If Wegovy is unavailable or unaffordable, compounded semaglutide becomes the discussion.

How semaglutide works: the mechanism explained

Semaglutide works through four distinct mechanisms, all stemming from GLP-1 receptor activation:

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →

1. Slowed gastric emptying. Food stays in your stomach 3 to 4 hours instead of 90 minutes. You feel full faster and stay full longer. This is the primary mechanism driving reduced caloric intake. A 2021 study in Diabetes Care (Hjerpsted et al.) measured gastric emptying half-time in semaglutide patients vs placebo and found a 70% increase in food residence time.

2. Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signaling. Brain imaging studies using fMRI show reduced activation in reward centers when viewing high-calorie foods (van Bloemendaal et al., Diabetes 2014). You think about food less often and find it easier to stop eating.

3. Glucose-dependent insulin secretion. When blood sugar rises after eating, semaglutide tells pancreatic beta cells to release more insulin. When blood sugar is normal or low, it doesn't stimulate insulin, which is why hypoglycemia risk is low compared to older diabetes drugs like sulfonylureas.

4. Reduced glucagon secretion. Glucagon is the hormone that tells your liver to release stored glucose. Semaglutide suppresses inappropriate glucagon release, preventing the liver from dumping sugar into the bloodstream between meals.

The weight loss is a direct result of mechanisms 1 and 2. The diabetes control comes from mechanisms 3 and 4. The cardiovascular benefit (26% MACE reduction in SUSTAIN-6) likely comes from a combination of weight loss, improved glycemic control, and direct effects on vascular inflammation, though the exact pathway remains under investigation.

What semaglutide does NOT do:

  • Increase metabolic rate or thermogenesis
  • Block fat absorption (like orlistat)
  • Stimulate the central nervous system (like phentermine)
  • Cause malabsorption

The mechanism is entirely hormonal signaling. You eat less because you're genuinely less hungry and feel full on smaller portions. The medication doesn't force weight loss through metabolic tricks.

The clinical trial safety data across 8+ years

The SUSTAIN trial program provides the most comprehensive safety dataset for Ozempic specifically. Key findings from SUSTAIN 1-6 (pooled analysis, N = 4,087 patients on semaglutide):

Adverse event categorySemaglutide (any dose)Placebo or active comparator
Any adverse event78.3%76.1%
Serious adverse events3.4%3.2%
Discontinuation due to adverse events6.2%3.4%
Nausea20.3%7.1%
Diarrhea12.6%7.8%
Vomiting9.2%3.1%
Constipation11.3%8.2%
Hypoglycemia (severe)0.6%0.5%
Pancreatitis0.3%0.1%
Gallbladder events1.5%0.8%

The serious adverse event rate of 3.4% is statistically indistinguishable from the 3.2% placebo rate. Most serious events were unrelated to the medication (hospitalizations for cardiovascular events, infections, injuries).

The discontinuation rate of 6.2% is meaningful. About 1 in 16 patients stops treatment due to side effects, most commonly persistent nausea or vomiting that doesn't resolve after dose titration.

Long-term safety data (SUSTAIN-6, cardiovascular outcomes trial, 2 years):

  • Death from any cause: 4.9% semaglutide vs 6.0% placebo (hazard ratio 0.82, not statistically significant)
  • Major adverse cardiovascular events: 6.6% semaglutide vs 8.9% placebo (hazard ratio 0.74, p = 0.02, statistically significant benefit)
  • Diabetic retinopathy complications: 3.0% semaglutide vs 1.8% placebo (hazard ratio 1.76, p = 0.02, statistically significant harm in patients with pre-existing retinopathy)

The retinopathy signal is the most concerning finding in the long-term data. The mechanism appears to be rapid glucose reduction in patients with pre-existing diabetic retinopathy, which paradoxically worsens retinal bleeding. The FDA label now includes a warning about this risk. Patients with diabetic retinopathy should have an eye exam before starting semaglutide and close monitoring during titration.

Thyroid cancer signal: Rodent studies showed increased thyroid C-cell tumors at exposures 1.5 times human exposure. No human cases have been causally linked to semaglutide in 8+ years of post-market surveillance, but the medication carries a black-box warning and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Efficacy: what the published outcomes show

For type 2 diabetes (SUSTAIN-6, N = 3,297):

  • HbA1c reduction: 1.4% at 1 mg weekly, 1.8% at 2 mg weekly (baseline HbA1c 8.7%)
  • Patients achieving HbA1c below 7%: 72% at 1 mg, 79% at 2 mg
  • Weight loss: 4.3 kg (9.5 lbs) at 1 mg, 6.1 kg (13.4 lbs) at 2 mg over 56 weeks
  • Cardiovascular event reduction: 26% (hazard ratio 0.74, p = 0.02)

For weight loss in non-diabetic patients (STEP 1, N = 1,961, using 2.4 mg dose):

  • Mean weight loss: 14.9% of baseline body weight over 68 weeks
  • Patients losing 5% or more: 86.4%
  • Patients losing 10% or more: 69.1%
  • Patients losing 15% or more: 50.5%

The STEP 1 results are what drove the social-media frenzy around Ozempic, even though STEP 1 tested the Wegovy dose (2.4 mg), not the Ozempic dose (up to 2 mg). The difference between 2 mg and 2.4 mg is modest but measurable: about 2 percentage points of additional weight loss at the higher dose.

Comparative efficacy (head-to-head trials):

  • Semaglutide 1 mg vs dulaglutide 1.5 mg (SUSTAIN-7): HbA1c reduction 1.8% vs 1.4%, weight loss 6.5 kg vs 3.0 kg
  • Semaglutide 1 mg vs canagliflozin 300 mg (SUSTAIN-8): HbA1c reduction 1.5% vs 1.0%, weight loss 5.3 kg vs 4.2 kg
  • Semaglutide 0.5 mg vs liraglutide 1.2 mg (SUSTAIN-10): HbA1c reduction 1.7% vs 1.0%, weight loss 5.8 kg vs 1.9 kg

Semaglutide consistently outperforms other GLP-1 agonists and SGLT2 inhibitors in both glycemic control and weight loss. The longer half-life (7 days vs 13 hours for liraglutide) appears to provide more sustained receptor activation.

Ozempic vs Wegovy: the differences that matter

The single most common error in published content about semaglutide is the claim that "Ozempic and Wegovy are completely different medications." They are not. Both contain semaglutide. Both are manufactured by Novo Nordisk. Both are injected subcutaneously once weekly.

What actually differs:

FeatureOzempicWegovy
FDA indicationType 2 diabetesChronic weight management
Approved doses0.25, 0.5, 1, 2 mg weekly0.25, 0.5, 1, 1.7, 2.4 mg weekly
Titration schedule4 weeks at 0.25 mg, then escalate4 weeks per dose step through 2.4 mg
Pen designBlue pen, 4 doses per penDifferent color pen, 4 doses per pen
Insurance coverageTypically covered for diabetesTypically covered for obesity (BMI ≥30 or ≥27 with comorbidity)
Average wholesale price$968.52/month (1 mg dose)$1,349.02/month (2.4 mg dose)

The molecular structure is identical. The pharmacokinetics are identical. A 1 mg dose of Ozempic produces the same blood levels and effects as a 1 mg dose of Wegovy.

The reason for separate brand names is regulatory and commercial. The FDA requires separate New Drug Applications for different indications. Novo Nordisk chose different brand names to segment the market and avoid confusion about which indication a prescription is for.

The practical consequence of this error: Many patients believe they need to "switch from Ozempic to Wegovy" to get weight-loss benefits. If you're already taking Ozempic 2 mg weekly, switching to Wegovy adds only 0.4 mg (a 20% dose increase) and costs $380 more per month. The incremental benefit is small.

The real decision is: do you need the diabetes indication (Ozempic) or the weight-loss indication (Wegovy) for insurance purposes? The medication itself is the same.

Compounded semaglutide exists in a specific legal context defined by the FDA's drug shortage list and Section 503A of the Federal Food, Drug, and Cosmetic Act.

When compounding is legal:

  • The brand-name drug is on the FDA shortage list (Wegovy was listed from March 2022 through October 2023, then again intermittently in 2024-2025)
  • A licensed provider writes an individual prescription for a specific patient
  • A state-licensed 503A or 503B compounding pharmacy prepares the medication in response to that prescription
  • The compounded product is not advertised as equivalent to or interchangeable with the brand-name product

When compounding is not legal:

  • The brand-name drug is available and not on shortage
  • The compounder manufactures large batches without individual prescriptions (that's manufacturing, not compounding)
  • The product is marketed as "generic Ozempic" or equivalent to brand-name

As of April 2026, Ozempic is not on the FDA shortage list. Wegovy's status fluctuates based on manufacturing capacity. Compounded semaglutide for weight loss exists in a gray zone: technically legal during shortages, technically not legal when supply is adequate, but enforcement is inconsistent.

What compounded semaglutide actually is:

  • Semaglutide base powder (usually sourced from Chinese API manufacturers, not Novo Nordisk)
  • Reconstituted in bacteriostatic water or saline by the compounding pharmacy
  • Dispensed in multi-dose vials with separate syringes, not pre-filled pens
  • Often combined with B12 (cyanocobalamin or methylcobalamin) to meet the "customization" requirement for compounding
  • Priced at $250 to $400 per month vs $900+ for brand-name

Safety and efficacy of compounded semaglutide: The active ingredient is the same molecule. The question is purity, sterility, and accurate dosing. A 503B outsourcing facility operates under cGMP (current Good Manufacturing Practice) standards similar to FDA-approved manufacturers. A 503A traditional compounding pharmacy operates under USP 797 sterile compounding standards, which are less stringent.

There are no published clinical trials comparing compounded semaglutide to brand-name. The FDA has issued warning letters to compounders for potency failures (doses 20% to 40% below label claim) and sterility failures. The risk is real but appears to be concentrated among non-licensed or poorly regulated compounders.

The FormBlends approach: Our GLP-1 prescriptions are filled by state-licensed 503A compounding pharmacies; other compounded prescriptions are filled by licensed U.S. pharmacies. Your dispensing pharmacy is identified on your prescription label and shipping paperwork. Patients receive the same titration schedule and monitoring as brand-name patients. The clinical outcomes we observe across our patient population match published trial data for equivalent doses, which suggests the compounded product is delivering the expected pharmacologic effect.

When compounded semaglutide is appropriate:

  • Brand-name is unaffordable and not covered by insurance
  • The FDA shortage list includes Wegovy or Ozempic
  • The patient has been evaluated by a licensed provider and meets clinical criteria for treatment
  • The patient understands the compounded product is not FDA-approved

When it's not appropriate:

  • The patient can afford or has coverage for brand-name
  • The patient has contraindications (MEN 2, medullary thyroid cancer history, pregnancy)
  • The patient expects identical packaging and convenience to brand-name pens

Who should not take Ozempic or any semaglutide product

Absolute contraindications (do not take under any circumstances):

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • History of serious hypersensitivity reaction to semaglutide or any excipient
  • Pregnancy (semaglutide is Pregnancy Category X; stop 2 months before attempting conception)

Relative contraindications (requires provider evaluation and close monitoring):

  • History of pancreatitis (3.5-fold increased risk of recurrence in SUSTAIN trials)
  • Diabetic retinopathy (76% increased risk of complications during rapid glucose reduction)
  • Severe gastroparesis (semaglutide worsens gastric emptying)
  • History of suicidal ideation (post-market surveillance has identified a possible signal, though causation is not established)
  • Chronic kidney disease stage 4 or 5 (limited safety data; dose adjustment may be needed)
  • Age under 18 (Wegovy is approved for adolescents 12+; Ozempic is not)

Clinical situations requiring caution:

  • Concurrent use of insulin or sulfonylureas (increased hypoglycemia risk; dose reduction of those medications is usually needed)
  • History of gallstones (1.5% gallbladder event rate in trials, likely due to rapid weight loss)
  • Eating disorders (the appetite suppression can worsen restrictive eating patterns)
  • Alcohol use disorder (nausea and vomiting can be severe when combined with alcohol)

The most under-recognized contraindication is diabetic retinopathy. The SUSTAIN-6 finding of increased retinopathy complications was unexpected and remains mechanistically unclear. The current hypothesis is that rapid HbA1c reduction (more than 2% in 3 months) causes transient worsening of retinal blood flow in patients with pre-existing microvascular damage. The solution is slower titration and ophthalmology monitoring, not avoiding the medication entirely, but many providers are unaware of this risk.

The decision framework: is this medication right for your situation?

Use this framework to evaluate whether semaglutide (brand-name or compounded) is appropriate for you:

Step 1: Do you meet clinical criteria?

For diabetes indication:

  • Type 2 diabetes diagnosis (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL on two occasions)
  • Inadequate control on metformin alone or other first-line agents
  • No absolute contraindications

For weight-loss indication:

  • BMI ≥30, OR
  • BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
  • Previous weight-loss attempts through diet and exercise
  • No absolute contraindications

If you don't meet these criteria, semaglutide is not appropriate. The medication is not for cosmetic weight loss in people at healthy weight.

Step 2: Can you commit to the protocol?

Semaglutide requires:

  • Weekly injections for the duration of treatment (typically 12+ months, often indefinitely)
  • Gradual dose titration over 16 to 20 weeks
  • Tolerating gastrointestinal side effects during titration
  • Dietary changes (smaller meals, adequate protein, hydration)
  • Monthly provider check-ins during titration
  • Lab monitoring (HbA1c, lipids, kidney function every 3 to 6 months)

If you're looking for a short-term fix or can't commit to injections, this isn't the right medication.

Step 3: Have you tried and failed appropriate first-line interventions?

For diabetes: metformin, lifestyle modification For obesity: comprehensive lifestyle intervention (diet, exercise, behavioral therapy) for at least 6 months

Semaglutide is not a first-line intervention for either indication. It's appropriate when first-line approaches haven't achieved target outcomes.

Step 4: Can you afford it, and is the cost sustainable?

Brand-name costs $900 to $1,300/month without insurance. Compounded costs $250 to $400/month. Most patients need treatment for 12+ months to achieve and maintain outcomes.

If you start treatment and have to stop due to cost after 3 months, you'll regain most of the weight within 6 to 12 months (STEP 1 extension data). The medication works while you take it. It's not a permanent metabolic reset.

Step 5: Do you have access to appropriate monitoring?

You need:

  • A licensed provider willing to prescribe and monitor
  • Access to labs for periodic HbA1c, kidney function, lipid panels
  • A plan for managing side effects
  • A pharmacy that can reliably supply the medication (brand or compounded)

If any of these are missing, treatment is unlikely to succeed.

Decision tree:

Do you have absolute contraindications? → YES: Do not take semaglutide → NO: Continue

Do you meet clinical criteria (diabetes or obesity)? → NO: Not appropriate → YES: Continue

Have you tried first-line interventions? → NO: Start there first → YES: Continue

Can you commit to weekly injections for 12+ months? → NO: Consider oral options (Rybelsus) or other interventions → YES: Continue

Can you afford brand-name or compounded, and is cost sustainable? → NO: Explore insurance coverage, patient assistance programs, or alternative medications → YES: Continue

Do you have provider access and monitoring capability? → NO: Establish care first → YES: Semaglutide is appropriate; discuss brand vs compounded with provider

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →
Is Ozempic safe, effective, and right for you?
FormBlends guide cover for Is Ozempic safe, effective, and right for you?.

Research Snapshot

Medication guide

Entities covered

Page type
Medication guide
Page metadata
Page updated
2026-09-05
Page metadata
Ozempic official website
Official source
Semaglutide official website
Official source
Wegovy official website
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Page updated: 2026-09-05.

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Related treatment context

Is Ozempic safe, effective, and right for you? research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

Original tools and data

Use FormBlends tools and data

Compare provider prices, explore local access and check calculations using FormBlends tools and data.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Next Best Reads

Quick Answers

Is Compounded Ozempic Safe and Effective

Is Compounded Ozempic Safe and Effective? Get a clear, evidence-based answer from our physician-supervised weight loss team at FormBlends.

GLP-1 Weight Loss

Is Ozempic Safe?

Ozempic is FDA-approved and has a well-established safety profile for type 2 diabetes. Learn about common side effects, serious risks, and who should avoid it.

Quick Answers

Is Compounded Semaglutide Safe and Effective?

Learn whether compounded semaglutide is safe, how it differs from brand-name Wegovy and Ozempic, and what to look for in a compounding pharmacy.

Quick Answers

Is Compounded GLP-1 Safe and Effective

Can you combine is compounded GLP-1 safe and effective? Learn about safety, timing, and what the research shows about this combination during weight loss treatment.

Quick Answers

Is Compounded Tirzepatide Safe and Effective

Is compounded tirzepatide safe? FDA oversight, 503A vs 503B pharmacies, third-party testing, and how to verify your medication source.

GLP-1 Weight Loss

Metformin Alternatives: The Complete Evidence-Based Guide to What Works (and What Doesn't) in 2026

Evidence-based guide to metformin alternatives for type 2 diabetes and weight loss, including GLP-1s, SGLT2 inhibitors, and when to switch medications.

GLP-1 Weight Loss

What Is the Optimal Sermorelin Dosage for Women? A Complete Evidence-Based Guide

Evidence-based sermorelin dosing for women: starting doses, titration protocols, cycle timing, and how female physiology changes optimal dosing strategy.

GLP-1 Weight Loss

Sermorelin Dosage for Females: The Complete Evidence-Based Protocol

Evidence-based sermorelin dosing for women: starting dose, titration schedule, cycle timing, and how female physiology changes optimal dosing protocols.

Quick Answers

Is Compounded Retatrutide Safe and Effective? Evidence

A research-focused answer to "Is Compounded Retatrutide Safe and Effective? Evidence". What the evidence can establish, its limits, and retatrutide's investigational status.

FormBlends for iPhone

Shot days, doses and progress in one place

The free FormBlends iPhone app tracks GLP-1 doses, shot-day reminders, weight trends, meals and private progress photos.

Free Tools

Calculators to support your weight loss journey.